TY - JOUR
T1 - Effects of Bumetanide on Neurocognitive Functioning in Children with Autism Spectrum Disorder
T2 - Secondary Analysis of a Randomized Placebo-Controlled Trial
AU - van Andel, Dorinde M.
AU - Sprengers, Jan J.
AU - Königs, Marsh
AU - de Jonge, Maretha V.
AU - Bruining, Hilgo
N1 - Funding Information: The study was supported by the Netherlands Organisation for Health Research and Development (ZonMw; grant number GGG - #836041015) (ZonMw Offroad Program grant number 04510011910052) and the NewTDEC Netherlands Organization for Scientific Research (NWO) Dutch National Research Agenda, NWA-ORC Call (NWA.1160.18.200). Neither the funder of the study, nor Neurochlore, who provided the study medication, had a role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication. Publisher Copyright: © 2022, The Author(s).
PY - 2023
Y1 - 2023
N2 - We present the secondary-analysis of neurocognitive tests in the ‘Bumetanide in Autism Medication and Biomarker’ (BAMBI;EUDRA-CT-2014-001560-35) study, a randomized double-blind placebo-controlled (1:1) trial testing 3-months bumetanide treatment (≤ 1 mg twice-daily) in unmedicated children 7–15 years with ASD. Children with IQ ≥ 70 were analyzed for baseline deficits and treatment-effects on the intention-to-treat-population with generalized-linear-models, principal component analysis and network analysis. Ninety-two children were allocated to treatment and 83 eligible for analyses. Heterogeneous neurocognitive impairments were found that were unaffected by bumetanide treatment. Network analysis showed higher modularity after treatment (mean difference:-0.165, 95%CI:-0.317 to − 0.013,p =.034) and changes in the relative importance of response inhibition in the neurocognitive network (mean difference:-0.037, 95%CI:-0.073 to − 0.001,p =.042). This study offers perspectives to include neurocognitive tests in ASD trials.
AB - We present the secondary-analysis of neurocognitive tests in the ‘Bumetanide in Autism Medication and Biomarker’ (BAMBI;EUDRA-CT-2014-001560-35) study, a randomized double-blind placebo-controlled (1:1) trial testing 3-months bumetanide treatment (≤ 1 mg twice-daily) in unmedicated children 7–15 years with ASD. Children with IQ ≥ 70 were analyzed for baseline deficits and treatment-effects on the intention-to-treat-population with generalized-linear-models, principal component analysis and network analysis. Ninety-two children were allocated to treatment and 83 eligible for analyses. Heterogeneous neurocognitive impairments were found that were unaffected by bumetanide treatment. Network analysis showed higher modularity after treatment (mean difference:-0.165, 95%CI:-0.317 to − 0.013,p =.034) and changes in the relative importance of response inhibition in the neurocognitive network (mean difference:-0.037, 95%CI:-0.073 to − 0.001,p =.042). This study offers perspectives to include neurocognitive tests in ASD trials.
KW - ASD
KW - Bumetanide
KW - Child
KW - Cognition
KW - Neurocognitive functioning
KW - RCT
UR - http://www.scopus.com/inward/record.url?scp=85145889834&partnerID=8YFLogxK
U2 - https://doi.org/10.1007/s10803-022-05841-3
DO - https://doi.org/10.1007/s10803-022-05841-3
M3 - Article
C2 - 36626004
SN - 0162-3257
JO - Journal of Autism and Developmental Disorders
JF - Journal of Autism and Developmental Disorders
ER -